Fluence by OSRAM Experts Join Speaker Lineups at Global Horticulture and Cannabis Conferences This Fall
23.9.2021 18:54:00 EEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its upcoming schedule of speakers who will present at virtual and in-person horticulture and cannabis industry conferences this fall.
“We’re thrilled our speakers are joining industry thought leaders from across the world to share their deep knowledge with cultivators, researchers, partners and others,” said David Cohen, CEO of Fluence. “At Fluence, our experts lead with science and are dedicated to advancing the industry’s awareness and application of LED lighting technologies to better understand the interaction between light and life. We look forward to connecting with conference participants, engaging in valuable conversations and discussing insights and learnings about what’s possible for LED lighting technology.”
Fluence’s roster of speakers includes:
- NCIA’s Midwest Cannabis Business Conference: Corinne Wilder, vice president of global operations, will speak with Dario Boyce from Anderson Porter Design and Jesse Porter from Inspire Transpiration Solutions on Sept. 23 at 12:00 p.m. CST about guidelines and policy for resource efficiency, including HVAC, lighting and control systems.
- NYC AgTech Week: Steve Graves, vice president of business development, will speak with Alina Zolotareva from AeroFarms, Tisha Livingston from Infinite Acres, Dr. Mary Ellis from Earle & Associates Ltd. and Penny McBride from FarmTech Society on Sept. 24 at 1:45 p.m. CST about trends in global controlled environment agriculture.
-
GreenTech Amsterdam:
- Timo Bongartz, general manager of EMEA, will speak with Brad Nattrass from urban-gro and Nic Easley from 3C Consulting, LLC on Sept. 29 at 8:00 a.m. CST about market insights, challenges and opportunities for medical cannabis.
- Leo Lansbergen, horticulture service specialist, will speak with Max van den Hemel from Delphy Improvement Centre, Marc van Oers from Van Iperen International and Eri Hayashi from the Japan Plant Factory Association on Sept. 28 at 5:15 a.m. CST about crop management and optimization.
- Theo Tekstra, technical director, will speak with Lisanne Meulendijks from Delphy Improvement Centre, Andrew Jenkins from TU Delft and Aleksander Nastov from Samsung on Sept. 29 at 7:00 a.m. CST about vertical farming.
- HortiCann Light + Tech: Dr. Abhay Thosar, director of horticulture services, will speak with Adam Shinners from Superior Fresh on Sept. 29 at 3:00 p.m. CST about sustainability and best cultivation practices, efficiencies and optimized lighting strategies in commercial food production.
- Indoor Ag-Con: Steve Graves, vice president of business development, will participate in a panel on Oct. 4 at 9:30 a.m. CST about the next technical frontier for lighting.
- Benzinga Cannabis Capital Conference: David Cohen, CEO of Fluence, will give an exclusive on-stage interview during Benzinga’s hybrid event on Oct. 15 at 12:10 p.m. CST.
- MJBizCon: Corinne Wilder, vice president of global operations, will speak with David Hess from Tress Capital and Derek Smith from the Resource Innovation Institute on Oct. 22 at 12:30 p.m. CST about environmental and sustainability practices.
- 2021 Plant Lighting Short Course: Dr. David Hawley, principal scientist, will speak on Oct. 28 at 1:00 p.m. CST about lighting for indoor agriculture.
- Grow Up Conference & Expo: Taylor Kirk, horticulture service specialist, will join cannabis experts on Dec. 1 at 9:15 a.m. CST to discuss growers’ experiences and expectations with LED lighting in cannabis cultivation.
For information about Fluence’s upcoming speaking engagements, including more presentation details, how to register and how to contact the Fluence team at their upcoming conferences, visit www.fluence.science/events-main.
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005773/en/
Contact information
Media Contact:
For Fluence, Pam Olszewski
pr@fluencebioengineering.com
C: 512-662-8551
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom